RARE - Ultragenyx Pharmaceutical Inc.
| Previous Close | 43.37 |
| Open | 43.20 |
| Bid | 41.37 x 1300 |
| Ask | 44.99 x 800 |
| Day's Range | 42.17 - 44.60 |
| 52 Week Range | 37.44 - 90.98 |
| Volume | 1,365,747 |
| Avg. Volume | 524,447 |
| Market Cap | 2.456B |
| Beta (3Y Monthly) | 2.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -7.01 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 74.83 |
- GuruFocus.com
Ultragenyx Pharmaceutical Inc (RARE) President & CEO Emil D Kakkis Bought $218,150 of Shares
President & CEO of Ultragenyx Pharmaceutical Inc (30-Year Financial, Insider Trades) Emil D Kakkis (insider trades) bought 5,000 shares of RARE on 09/11/2019 at an average price of $43.63 a share. Continue reading...
- Zacks
Ultragenyx to Submit sBLA for Label Expansion of Crysvita
Ultragenyx (RARE) and partner Kyowa Kirin plan to submit an sBLA to the FDA for the label expansion of Crysvita.
- GlobeNewswire
Ultragenyx and Kyowa Kirin Announce Intent to Submit Supplemental Biologics License Application to U.S. FDA for Crysvita® (burosumab) in Tumor-Induced Osteomalacia (TIO)
NOVATO, Calif. and TOKYO, Sept. 10, 2019 -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and.
- Zacks
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
- GlobeNewswire
Ultragenyx Announces Positive Data from Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced positive data from the second dose cohort of the ongoing Phase 1/2 study of DTX401, an adeno-associated virus (AAV) based gene therapy for the treatment of glycogen storage disease type Ia (GSDIa). All three patients in Cohort 2 have shown a clinical response with improvements in glucose control and other metabolic parameters compared to baseline.
- Simply Wall St.
Is Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Trading At A 36% Discount?
Does the September share price for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) reflect what it's really worth? Today...
- GlobeNewswire
GeneTx and Ultragenyx Announce Orphan Drug Designation and Rare Pediatric Disease Designation for GTX-102
GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation and Rare Pediatric Disease Designation to GTX-102 for the treatment of Angelman Syndrome, a serious, debilitating rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide. “The granting of these designations from the FDA is an enormous milestone for the Angelman community,” stated Paula Evans, Chief Executive Officer of GeneTx.
- Zacks
Ultragenyx (RARE) Down 9.9% Since Last Earnings Report: Can It Rebound?
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- GlobeNewswire
Ultragenyx to Present at Upcoming Investor Conferences
The live and archived webcast of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases.
- Zacks
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
- Investor's Business Daily
This Biotech Stock Just Roped In A New Partner — And A Potential Buyout
Ultragenyx Pharmaceutical will pay $20 million to partner with — and potentially acquire — biotech startup GeneTx as it studies a treatment for a rare disease called Angelman syndrome.
- GlobeNewswire
Ultragenyx Announces Partnership with GeneTx to Advance Treatment for Angelman Syndrome
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, and GeneTx Biotherapeutics LLC, today announced a partnership to develop GeneTx’s GTX-102, an antisense oligonucleotide (ASO) for the treatment of Angelman syndrome, a serious, debilitating, rare neurogenetic disorder that affects approximately 1 in 15,000 people worldwide. GTX-102 is currently in late preclinical development with an investigational new drug (IND) application expected to be filed with the U.S. Food and Drug Administration (FDA) in the first half of 2020.
- GlobeNewswire
Ultragenyx to Present at Wedbush PacGrow Healthcare Conference
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Tom Kassberg, the company’s Chief Business Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 1:20 PM ET in New York, NY. The live and archived webcast of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. Ultragenyx is a biopharmaceutical company committed to bringing patients novel products for the treatment of serious rare and ultra-rare genetic diseases.
- Zacks
Amicus (FOLD) Q2 Earnings Match, Stock Falls on Weak Q3 View
Amicus' (FOLD) earnings meet estimates in the second quarter while revenues beat the same.
- Thomson Reuters StreetEvents
Edited Transcript of RARE earnings conference call or presentation 1-Aug-19 9:00pm GMT
Q2 2019 Ultragenyx Pharmaceutical Inc Earnings Call
- Zacks
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q2
Ultragenyx (RARE) posts wider-than-expected loss but beats on sales in the second quarter of 2019.
Motley FoolUltragenyx Pharmaceutical Inc (RARE) Q2 2019 Earnings Call Transcript
RARE earnings call for the period ending June 30, 2019.
- Zacks
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.94% and 11.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Ultragenyx Reports Second Quarter 2019 Financial Results and Corporate Update
Strong Crysvita® (burosumab) Launch Continues with Approximately 960 Patients on Reimbursed Commercial Therapy in the United States Ultragenyx Submits New Drug Application to.
- GlobeNewswire
Ultragenyx Announces Submission of New Drug Application to FDA for UX007 (triheptanoin) for Treatment of Long-Chain Fatty Acid Oxidation Disorders
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) a New Drug Application (NDA) for UX007 (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), a group of genetic disorders in which the body is unable to convert long-chain fatty acids into energy. The FDA previously granted Rare Pediatric Disease Designation and Fast Track designation, which enables eligibility for Priority Review, if relevant criteria are met.
- Zacks
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Ultragenyx to Host Conference Call for Second Quarter 2019 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, August 1, 2019 at 5pm ET to discuss second quarter 2019 financial results and provide a corporate update. Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
- Simply Wall St.
Why Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Is A Financially Healthy Company
Small-caps and large-caps are wildly popular among investors; however, mid-cap stocks, such as Ultragenyx...
- GlobeNewswire
Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.
NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.
- Zacks
Arcturus Metabolic Disorder Candidate Gets Orphan Drug Status
The FDA grants orphan drug designation to Arcturus Therapeutics' (ARCT) candidate, ARCT-810 for treating patients with ornithine transcarbamylase deficiency, the most common urea cycle disorder.
